Analytical Data
-
Gene name
PLA2G1B
- Application
-
Alternative Names
PLA2G1B; PLA2A; PPLA2; Phospholipase A2, Group IB; Group IB phospholipase A2; Phosphatidylcholine 2-acylhydrolase 1B
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
P04054
-
Expression Region
Asp16~Ser148
-
Molecular Weight
19kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PLA2G1B, or phospholipase A2 group IIB, is a member of the phospholipase A2 (PLA2) enzyme family, which plays crucial roles in various biological processes by hydrolyzing phospholipids to release arachidonic acid and lysophospholipids. The research surrounding PLA2G1B has gained significant interest due to its involvement in inflammation, cell signaling, and membrane dynamics. This enzyme is expressed in various tissues, including the pancreas, where it contributes to digestive processes, and the brain, where it may influence neuroinflammatory responses. Additionally, aberrant expression of PLA2G1B has been linked to pathological conditions such as cancer, cardiovascular diseases, and neurodegenerative disorders, highlighting its potential as a therapeutic target. The development of recombinant PLA2G1B protein facilitates detailed studies on its biochemical properties, structural biology, and interactions with ligands, thereby enhancing our understanding of its functional mechanisms. Furthermore, studying the protein’s expression, activity, and regulation may pave the way for novel strategies in designing inhibitors or modulators, which could have therapeutic implications in diseases where PLA2G1B is implicated. As such, research on recombinant PLA2G1B not only contributes foundational knowledge to lipid metabolism and signaling pathways but also opens avenues for innovative biomedical applications.
